Monlunabant
Product Specifications
UNSPSC Description
Monlunabant ((S)-MRI-1891) is a solid dispersions compound, as well as a cannabinoid CB1 receptor inhibitor[1].
Target Antigen
Cannabinoid Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein;Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/monlunabant.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=S(N/C(N1N=C(C2=CC=C(C=C2)Cl)[C@@H](C3=CC=CC=C3)C1)=N/C(NC(C)=O)=N)(C4=CC=C(C=C4)C(F)(F)F)=O
Molecular Weight
591.00
References & Citations
[1]Liu Z, Iyer MR, Godlewski G, Jourdan T, Liu J, Coffey NJ, Zawatsky CN, Puhl HL, Wess J, Meister J, Liow JS, Innis RB, Hassan SA, Lee YS, Kunos G, Cinar R. Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB1R) Antagonist. ACS Pharmacol Transl Sci. 2021 Apr 8;4(3):1175-1187.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-153800/Monlunabant-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-153800/Monlunabant-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
2712480-46-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
